Pharming Group NV (NASDAQ:PHAR) — Market Cap & Net Worth
Market Cap & Net Worth: Pharming Group NV (PHAR)
Pharming Group NV (NASDAQ:PHAR) has a market capitalization of $1.18 Billion ($1.18 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8386 globally and #2298 in its home market, demonstrating a 2.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharming Group NV's stock price $16.98 by its total outstanding shares 69668824 (69.67 Million). Analyse cash efficiency ratio of Pharming Group NV to see how efficiently the company converts income to cash.
Pharming Group NV Market Cap History: 2020 to 2026
Pharming Group NV's market capitalization history from 2020 to 2026. Data shows growth from $1.06 Billion to $1.18 Billion (0.31% CAGR).
Index Memberships
Pharming Group NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.05% | #223 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #872 of 3165 |
Weight: Pharming Group NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharming Group NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharming Group NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.36x
Pharming Group NV's market cap is 2.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.06 Billion | $212.17 Million | $37.75 Million | 4.99x | 28.05x |
| 2021 | $622.84 Million | $198.87 Million | $16.00 Million | 3.13x | 38.94x |
| 2022 | $768.45 Million | $205.62 Million | $13.67 Million | 3.74x | 56.20x |
| 2023 | $796.31 Million | $245.32 Million | -$10.55 Million | 3.25x | N/A |
| 2024 | $701.22 Million | $297.20 Million | -$11.84 Million | 2.36x | N/A |
Competitor Companies of PHAR by Market Capitalization
Companies near Pharming Group NV in the global market cap rankings as of May 4, 2026.
Key companies related to Pharming Group NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Pharming Group NV Historical Marketcap From 2020 to 2026
Between 2020 and today, Pharming Group NV's market cap moved from $1.06 Billion to $ 1.18 Billion, with a yearly change of 0.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.18 Billion | -3.90% |
| 2025 | $1.23 Billion | +75.56% |
| 2024 | $701.22 Million | -11.94% |
| 2023 | $796.31 Million | +3.63% |
| 2022 | $768.45 Million | +23.38% |
| 2021 | $622.84 Million | -41.16% |
| 2020 | $1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Pharming Group NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more